Menarini SpA, Italy's major producer of pharmaceuticals for the domestic market, has rejected government proposals for price cuts in a series of combative public press advertisements, and has announced that it is to quit Italy and switch production to Germany.
The company, which employs some 5,200 people - 3,000 of them in Italy, timed its campaign to coincide with a meeting of the new Italian cabinet called to discuss extra health care reforms.
Menarini says it is not prepared to endure the distorted application of the law on average European pharmacy prices. The application of the legislation in Italy by the last government has "in fact imposed the lowest prices in Europe," it claims. The company adds that it is not prepared to accept a 10% cut in prices and that "instead of calling for a Europeanization that does not arrive," production will be transferred to Germany.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze